Description of Research Expertise
Drug dosing in dialysis
Drug nephrotoxicity
Cardiorenal syndrome
Intra-abdominal hypertension
Obesity and renal disease
Acute kidney injury
Resistant hypertension
Selected Publications
Pennekamp A, Wahba I: Importance of MAP reduction for AKI induction in type 1 cardiorenal syndrome Am J Kidney Dis : 2023.
Rudnick MR, Fay K, Wahba IM: Fluid administration strategies for the prevention of contrast-associated acute kidney injury Curr Opin Nephrol Hypertens 31 (5): 414-424,2022.
Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI: Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review Am J Kidney Dis 4 : 517-528,2021.
Rudnick M, Wahba IM, Miskulin D: Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease UpToDate : 2020- Current.
Srinivasan V, Ahmad S, Aggarwal S, Wahba I, Huan Y: COVID-19 infection patterns in an academic inner city dialysis unit Journal of the American Society of Nephrology : 2020.
Rudnick M, Wahba IM, Leonberg-Yoo A: Use of Gadolinium-Based Contrast Agents in Patients with Severe Renal Impairment. Absence of Risk Versus Caution: A Nephrologist’s Perspective Kidney360 1 (6): 433-435,2020.
Fink JC, Joy MS, St Peter WL, Wahba IM; ASN Chronic Kidney Disease Advisory Group.: Finding a common language for patient safety in CKD Clin J Am Soc Nephrol 7 (4): 689-95,2012.
Dadfarmay S, Wahba IM: Acute kidney injury due to pulmonary embolism: The case for congestive kidney failure Nephrol Dial Transplant Plus 4 : 295-298,2011.
Wahba IM: The renal consequences of obesity- What have we learned in recent years? US Nephrology 3 (2): 12-15,2009.
Cedergreen JC, Markin CJ, Wahba IM: Prevalence of Chronic Kidney Disease in Patients with Pulmonary Arterial Hypertension Am J of Respit and Crit Care Med 179 : A4864,2009.
Academic Contact Information
VAMC
3900 Woodland Ave
Philadelphia,
PA
19104
Phone: 215-662-7934